Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses.
Level 1 - systematic review of randomized trials
Systematic review of systematic reviews and meta-analyses
PubMed 36694884 · doi:10.17925/EE.2022.18.2.96
What was done
Authors conducted an umbrella review (systematic review of systematic reviews and meta-analyses) following a predefined protocol. Searches were performed across PubMed, Embase, and Cochrane CENTRAL for reviews examining statin use and new-onset diabetes mellitus (NODM) incidence. Two reviewers independently screened studies and extracted data. Methodological quality of included reviews was evaluated using the AMSTAR 2 tool.
What was found
From 621 initial records, 16 systematic reviews and meta-analyses were included. The abstract reports no numerical effect sizes or risk ratios. Statin use was reported to increase the risk of NODM, with risk heightened for atorvastatin and rosuvastatin, intensive dosing regimens, and older individuals. In contrast, pravastatin and pitavastatin were associated with lower or no risk. Quality appraisal with AMSTAR 2 revealed that the included reviews and meta-analyses were of critically low or low methodological quality.
Why it matters
This review synthesizes secondary evidence regarding statin-associated dysglycemia, reinforcing that cardiovascular benefits generally outweigh diabetes risk but warranting glycemic monitoring, particularly with high-intensity regimens.
Limits
The abstract provides no numerical risk estimates or confidence intervals. The primary limitation is the critically low or low methodological quality across the 16 included systematic reviews. Primary trials were not directly assessed, leaving potential study overlap and residual confounding unmeasured.
Cited by
- partial Pitavastatin is the one statin that does not increase the risk of developing type 2 diabetes.